Evaluation of the AIVARIX in Detecting Signs C 1-2 Classes of CVD
단계 해당 없음
완료
NCT05612217
| 대상 질환 | Chronic Venous Disease, CVD |
|---|
| 임상 단계 | 단계 해당 없음 |
|---|
| 스폰서 | Servier Russia |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 433 명 |
|---|
| 중재(약물) | to estimate Sensitivity and Specificity AIVARIX app in detecting C1 and C2 classes of CVD |
|---|
| 시작일 | 2022년 12월 1일 |
|---|
| 완료일 | 2023년 6월 1일 |
|---|
| 결과 공개일 | 2024년 9월 25일 |
|---|
요약
This study is a multicenter observational study, which is carried out in frame of routine clinical practice in Russia. The program will include patients suggestive to chronic venous diseases (CVDs) including but not limited to those with C1 and C2 classes by CEAP classification, who will be seeking professional phlebologists' consultation. Study conduction is scheduled in Russia in 2022-2023. The planned number of patients is 414
Evaluation of Sensitivity (Sn) of the AI-based AIVARIX App in Detecting C1 and C2 Classes of CVD in Patients Who Are Seeking for Professional Advice From a Phlebologist Regarding Symptoms and Signs Suggestive to CVD.
1 month · percentage of of positive cases
| Patients With CVD | 75.19 percentage of of positive cases |
|---|
Evaluation of Specificity (Sp) of the AI-based AIVARIX App in Detecting C1 and C2 Classes of CVD in Patients Who Are Seeking for Professional Advice From a Phlebologist Regarding Symptoms and Signs Suggestive to CVD
1 month · percentage of negative cases
| Patients With CVD | 86.51 percentage of negative cases |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.